Navigation Links
Americans Not Interested In Choosing Sex Of Child: Survey

dergo an average of three to five cycles of intrauterine insemination at a fertility centre, at a cost of approximately $2,500 per attempt.

The survey found that while the majority of respondents would not choose the sex of their child under these trying conditions, most would still not use the technology even under less demanding circumstances.

Only 12 percent would use sex selection technology if it were available in any doctor's office, if it required only a single cycle of intrauterine insemination, and if it were covered by health insurance.

Even if it were possible to choose the sex of a child simply by taking a 'blue pill' for a boy or a 'pink pill' for a girl, only 18 percent of respondents indicated they would do so. The rest were opposed or undecided.

'Perhaps this speaks to the fact that people still want to leave things up chance and not rely on science for everything,' said Jain.

In an earlier study, Jain and colleagues had reported that 40 percent of women being treated for infertility would choose the sex of their next child if given the option.

The discrepancy between the two studies is significant but not surprising, Jain said. Infertile couples may feel they have only one chance to have a child, while the general population assumes the opportunity for more children.

'This study should ease the fears of some of people who believe that sex selection technology will become widespread when it is readily available in the United States,' said Jain. 'There is no evidence that the technology will have a significant impact on the natural sex selection ratio.'

Edited IANS
'"/>




Page: 1 2

Related medicine news :

1. Poll Finds Many Americans Misinformed About Cancer
2. Poll Finds Many Americans Misinformed About Cancer
3. Hypertension Drug of Choice for African Americans
4. 38 million Americans including 14 million children left to combat hunger
5. Americans Consume Far Too Much Salt and Sodium
6. Americans Growing Out Of Shape
7. Rise in Stress among Americans
8. Home Remedies More Used By Blacks And Native Americans
9. 90 Million Americans Harbor Drug Resistant Bacteria Inside Their Nose
10. Aspirin, Not Used By African Americans And Diabetics To Prevent Heat Problems
11. Americans Avoiding Risky Foods
Post Your Comments:
(Date:12/6/2009)... Dec. 6 Pharmacyclics, Inc. (Nasdaq: ... Phase I/II study showing safety and clinical activity ... (NHL) treated with its HDAC inhibitor PCI-24781 as ... at the 51st ASH Annual Meeting being held ... ,, PCI-24781 is an oral pan-HDAC inhibitor which ...
(Date:12/6/2009)... DNA in virus , , SUNDAY, Dec. 6 (HealthDay News) -- ... found in a tiger that lived thousands or millions of ... virus took on a bit of a tiger,s genetic material, ... the virus to this day. That tiger, in fact, may ... virus that ultimately led to its infection of humans. , ...
(Date:12/6/2009)... study provides welcome news for patients with a common ... The condition is estimated to impact 62,000 Canadians and ... clot forms in a vein and restricts the flow ... the clot may detach from its point of origin ... a potentially fatal condition known as a pulmonary embolism. ...
(Date:12/5/2009)... been significant scientific advances in the field of blood ... understanding of how certain diseases progress in order to ... best care. Research presented today at the 51st Annual ... induction therapies for managing multiple myeloma, the importance of ...
(Date:12/5/2009)... experts advise , , SATURDAY, Dec. 5 (HealthDay News) -- ... can have bad reactions to certain holiday traditions and ... wheezing, according to the American College of Allergy, Asthma ... live evergreens may choose to decorate with artificial plants, ...
Breaking Medicine News(10 mins):Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Keep Asthma, Allergies at Bay for the Holidays 2
... June 2008: Infections during the first year of ... specific types of arthritis later in life, according to ... the Annual Congress of the European League Against Rheumatism ... Sweden found that infants who were hospitalised for infection ...
... New data presented today at EULAR 2008, the ... Paris, France, show that over half of rheumatoid arthritis ... or infliximab were added to their methotrexate treatment regimen, ... , The ATTEST (Abatacept or infliximab versus placebo, a ...
... BMJ debate the issue of selling kidneys. , ... the solution to the growing shortage of kidneys for transplantation, ... Minnesota. , In many areas of the United States ... is five years, but in some parts it is as ...
... candid about, recent publicized lead testing results; sites difficulty in confirming two ... ... Attorney Christopher Grell,ordered lab tests on behalf of his client on three ... the,Fraud Discovery Institute., On May 19th the Fraud Discovery Institute released ...
... Ascension Orthopedics, Inc., a,leader in orthopedic extremity implants, ... Warrender, Jr., John F. Walters and David,C. Furr, ... and,experience will make a substantial contribution to the ... on April 14 as Senior Vice President of,Global ...
... today that it has initiated a Phase 1 ... for the detection and staging of metastatic prostate ... small molecule radiopharmaceutical candidates that target prostate-specific membrane ... select a lead candidate for further development and ...
Other Medicine News:Health News:Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis 2Health News:Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients 2Health News:What's wrong with selling kidneys? 2Health News:Plaintiff's Lawyer Orders Lead Testing on 3 Popular Herbalife Products; Results Show 728% More Lead Than Allowed by Law Under Proposition 65 Violation 2Health News:Three Industry Veterans Join Ascension Orthopedics 2Health News:Three Industry Veterans Join Ascension Orthopedics 3Health News:Molecular insight begins Trofex Phase 1 trial for detection of metastatic prostate cancer 2
(Date:12/4/2009)... Depression, anxiety disorder, bipolar disorder, Attention Deficit ... are among the comorbidities reported to occur more ... diagnosed with epilepsy versus those without an epilepsy ... households across the U.S. ,, Findings from " ...
(Date:12/3/2009)... 3 Allen Medical Systems, a subsidiary of Hill-Rom ... the launch of its new Allen Amatech(TM) OEM (Original ... ,, The website reinforces the Allen Amatech(TM) brand ... product catalog, with detailed descriptions and design specifications for ...
(Date:12/3/2009)... 3 A genetic variation that may indicate a ... if exposed to certain pharmaceutical therapies or chemicals is ... leader Quest Diagnostics (NYSE: DGX ) will ... Annual Meeting and Exposition, December 5-8, 2009, in New ...
Breaking Medicine Technology:Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Medical Malpractice Victim Helps Uphold Constitutional Rights of Patients in Washington State Supreme Court Decision Perey Law Announces 57593 1Medical Malpractice Victim Helps Uphold Constitutional Rights of Patients in Washington State Supreme Court Decision Perey Law Announces 57593 2Medical Malpractice Victim Helps Uphold Constitutional Rights of Patients in Washington State Supreme Court Decision Perey Law Announces 57593 3HealthFitness to Present at the Canaccord Adams Healthy Living Conference 57590 1HealthFitness to Present at the Canaccord Adams Healthy Living Conference 57590 2Time to Turn the Town Pink 57587 1Time to Turn the Town Pink 57587 2
... ALUS ), the worldwide leader in intravascular ... featuring both patient cases and laboratory research in ... this week at the American,Society of Anesthesiologists (ASA) ... Arie Blitz, Director of Heart Transplantation and Assist ...
... TR-701 Phase 1 Clinical Trial Results Disclosed, ... Therapeutics, Inc., a,biopharmaceutical company developing "Best-in-Class" drugs ... today that the results,of multiple studies on ... pipeline,programs will be presented in eighteen presentations ...
Other Medicine Technology:Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 2Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 3Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 2Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 3
... quick and easy automated refill system ... space on your laboratory bench and ... easy-to-use, one-hand system, you only need ... of Diamond Tips. All sizes of ...
10 L, Stacked Rack, 96 tips/rack 5 racks/stack, clear Recommended for 2, 5, 10 L pipettes....
... been designed to optimize the accuracy and ... tip products is widely recognized by customers ... been extended over the years and now ... special tips including filter tips, certified pure ...
... HerpeSelect® 2 ELISA IgG test is intended ... human IgG class antibodies to HSV-2 in ... 1 ELISA IgG, the test is indicated ... for aiding in the presumptive,diagnosis of HSV ...
Medicine Products: